Strides Pharma gets USFDA approval for Levetiracetam Oral Solution

The Levetiracetam Oral Solution has a market size of around $55 million, according to data reported by IQVIA

Strides Pharma

Source: Strides Pharma Facebook

Sanket Koul New Delhi

Listen to This Article

Strides Pharma on Tuesday announced that its wholly-owned Singapore-based subsidiary, Strides Pharma Global Pte, has received approval from the United States Food and Drug Administration (USFDA) for Levetiracetam Oral Solution USP, 100 mg/mL. This generic drug is taken after the partial onset of seizures. The product is deemed bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Keppra Oral Solution, 100 mg/mL, of UCB, Inc.

The product will be manufactured at the company’s facility in Bengaluru. According to the US National Institute of Health, Levetiracetam is a prescription-based drug, taken orally, that is used to treat partial onset seizures in people aged 4 years and older with epilepsy. It is also used for myoclonic (brief and acyclic) seizures in people aged 12 years and older with juvenile myoclonic epilepsy.

The Levetiracetam Oral Solution has a market size of around $55 million, according to data reported by IQVIA.

Strides Pharma already has 260 cumulative Abbreviated New Drug Applications (ANDAs) filed with the USFDA, of which 230 have been approved.

Strides has also set a target to launch 60 new products over three years in the US, according to the company's statement.

On Tuesday, shares of Strides Pharma were up by 0.85 per cent, ending the day's trade at Rs 494.50 apiece on the BSE.

Also Read

Strides Pharma arm obtains USFDA nod for Levetiracetam oral solution

Strides Pharma Q1FY24 results: Net profit at Rs 8 cr; revenue up 12%

Stride Pharma Global receives USFDA approval or Efavirenz, other drugs

Strides Pharma soars 8% on USFDA nod for drug to treat heart diseases

Strides soars 11% on USFDA's tentative nod to generic HIV treatment drug

Volkswagen launches 'Sound' edition for Taigun, Virtus with enhanced audio

'KPMG expands operations in Kolkata, to double workforce by FY25'

Jindal Power will not bid to take over airline Go First, say reports

ED issues notice to Byju's for violation of forex rules, firm denies

Godrej Properties to meet Rs 14K-cr sales bookings target: Pirojsha Godrej

First Published: Nov 21 2023 | 4:50 PM IST

Explore News